Free tool
FAERS Monitor: Khapzory
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211226 or its brand name (Khapzory, Levoleucovorin). Reports on generic versions are filed under their own applications.
Reports
757
Serious
737
97% of reports
Hospitalization
211
Death reported
44
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neutropenia125
- thrombocytopenia78
- asthenia76
- off label use75
- diarrhoea64
- nausea60
- azotaemia59
- anaemia37
- vomiting35
- pyrexia30
- febrile neutropenia28
- neuropathy peripheral23
- hyperbilirubinaemia21
- constipation20
- leukopenia20
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 2 |
| 2012 | 8 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 71 |
| 2019 | 55 |
| 2020 | 19 |
| 2021 | 29 |
| 2022 | 55 |
| 2023 | 161 |
| 2024 | 140 |
| 2025 | 139 |
| 2026 | 66 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,402 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| azotaemiaSignal | 59 | 416.6 | 325.4 | 23,696 |
| hyperbilirubinaemiaSignal | 21 | 56.4 | 37.0 | 1,087 |
| neutropeniaSignal | 125 | 25.6 | 21.8 | 2,942 |
| thrombocytopeniaSignal | 78 | 19.4 | 15.7 | 1,349 |
| febrile neutropeniaSignal | 28 | 11.7 | 8.2 | 265 |
| leukopeniaSignal | 20 | 11.1 | 7.2 | 174 |
| neuropathy peripheralSignal | 23 | 6.7 | 4.5 | 107 |
| astheniaSignal | 76 | 5.6 | 4.5 | 289 |
| anaemiaSignal | 37 | 5.4 | 3.9 | 129 |
| diarrhoeaSignal | 64 | 2.8 | 2.2 | 72 |
| constipationSignal | 20 | 2.5 | 1.7 | 17 |
| pyrexiaSignal | 30 | 2.4 | 1.7 | 24 |
| off label useSignal | 75 | 2.4 | 1.9 | 61 |
| nauseaSignal | 60 | 2.1 | 1.7 | 35 |
| vomitingSignal | 35 | 2.1 | 1.5 | 19 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.